Clinical Trial Search

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants

Primary: Overall Survival — 289; 259 Days

Primary: Time to Progression (TTP) — 164; 112 days

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006

Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001

Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants

Primary: Time to Disease Progression — 8 months

Primary: Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging) — 75; 73 participants

Primary: One-Year Overall Survival Rate — 16 Participants

Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072

Primary: Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the…

Primary: Progression Free Survival (PFS) — 43 months

Primary: Overall Survival (OS) — 8.51; 7.29 Months — p=0.0199

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382

Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants

Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants

Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants

Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…